Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A S12* PIK3CA E542K |
Therapy | Carboplatin + Paclitaxel + Palbociclib |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A S12* PIK3CA E542K | lung squamous cell carcinoma | sensitive | Carboplatin + Paclitaxel + Palbociclib | Preclinical - Pdx | Actionable | In a preclinical study, the addition of Ibrance (palbociclib) to treatment with the combination of Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in improved tumor growth inhibition compared to chemotherapy or Ibrance (palbociclib) alone in a patient-derived xenograft (PDX) model of squamous non-small cell lung cancer harboring PIK3CA E542K and CDKN2A S12* (PMID: 39199558). | 39199558 |
PubMed Id | Reference Title | Details |
---|---|---|
(39199558) | Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients. | Full reference... |